![Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease | Scientific Reports Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-47287-1/MediaObjects/41598_2019_47287_Fig1_HTML.png)
Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease | Scientific Reports
![Acute Fingolimod Effects on Baroreflex and Cardiovascular Autonomic Control in Multiple Sclerosis - Vittorio Racca, Marco Rovaris, Rosella Cavarretta, Emanuele Vaini, Anastasia Toccafondi, Marco Di Rienzo, 2019 Acute Fingolimod Effects on Baroreflex and Cardiovascular Autonomic Control in Multiple Sclerosis - Vittorio Racca, Marco Rovaris, Rosella Cavarretta, Emanuele Vaini, Anastasia Toccafondi, Marco Di Rienzo, 2019](https://journals.sagepub.com/cms/10.1177/1179573519849945/asset/images/large/10.1177_1179573519849945-fig1.jpeg)
Acute Fingolimod Effects on Baroreflex and Cardiovascular Autonomic Control in Multiple Sclerosis - Vittorio Racca, Marco Rovaris, Rosella Cavarretta, Emanuele Vaini, Anastasia Toccafondi, Marco Di Rienzo, 2019
![IJMS | Free Full-Text | The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients IJMS | Free Full-Text | The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients](https://www.mdpi.com/ijms/ijms-19-02448/article_deploy/html/images/ijms-19-02448-g007.png)
IJMS | Free Full-Text | The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients
![Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr] Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS) Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr] Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)](https://mma.prnewswire.com/media/1019389/Teva_Canada_Limited_Teva_Canada_Announces_the_Launch_of_a_Bioequ.jpg?p=facebook)
Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr] Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)
![An Effective Approach to Assess Bioequivalence of Fingolimod in Normal Healthy Volunteers Using 0.5 mg Study Dose An Effective Approach to Assess Bioequivalence of Fingolimod in Normal Healthy Volunteers Using 0.5 mg Study Dose](https://www.biopharmaservices.com/wp-content/uploads/2021/10/study-print.png)
An Effective Approach to Assess Bioequivalence of Fingolimod in Normal Healthy Volunteers Using 0.5 mg Study Dose
![Cardiovascular effects of fingolimod: Relevance, detection and approach | Revista Portuguesa de Cardiologia Cardiovascular effects of fingolimod: Relevance, detection and approach | Revista Portuguesa de Cardiologia](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S2174204915000872:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w94UphxYc+GPca8Z7OggvdfJQF4SIqTc4zp8SrbcUWBiK3uEuMKe1NTN2jJ48cLpjHd+i6XTIs5WLVTAuctKvKmg2FQnJarUyK96Acp/03sVcWevP8sPzTSSUK7Y0Lb6mKC3Pd4mCDBimUmiAP6VduWvZSLLVvCp+Uh8vwrJy504QofdPgW1ohpmwW8WP16RiUtWOfSXGvIFDJOdTu3Llh4Gbvw/54pQwx7dYTm6srDIIKXf4CLmWhoYha4j0Fqb8ZVW1NGqY59W0CN2KV+gfzp8=)